Fremanezumab blocks CGRP induced dilatation in human cerebral, middle meningeal and abdominal arteries
Abstract Background Fremanezumab (TEV-48125) is a fully humanized anti-calcitonin gene-related peptide (CGRP) monoclonal antibody (mAb) that has shown positive results in the prevention of episodic migraine and chronic migraine. Previous preclinical studies have revealed CGRP antagonistic effects on...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-08-01
|
Series: | The Journal of Headache and Pain |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s10194-018-0905-8 |